On December 31, the Joint Prevention and Control Mechanism of the State Council was released. Sinopharm's China Bio-New Crown Inactivated Vaccine has been approved by the State Food and Drug Administration for conditional listing.
Existing data show that the protection rate is 79.34%, achieving the unity of safety, effectiveness, accessibility, and affordability, and meeting the relevant standards of the World Health Organization and the National Food and Drug Administration.
In the future, the durability and protective effect of vaccine immunity need to be continuously observed.
This achievement has not come easily. The listing of Chinese vaccines has injected confidence in the global fight against the epidemic and also provided strong support for vaccines to become a global public product.
Image source: Xinhua Viewpoint
my country's 3 technical routes and 5 vaccines enter phase III clinical trials
Xu Nanping, vice minister of science and technology, said at the State Council’s joint prevention and control mechanism press conference on the 31st that so far, 14 vaccines from 5 technical routes in my country have entered clinical trials, of which 3 technical routes and 5 vaccines have entered phase III clinical trials.
Xu Nanping said that on December 30, Beijing Institute of Biological Products Co., Ltd. announced the results of the interim analysis data of the phase III clinical trial of the new crown virus inactivated vaccine, and its protective effect reached the relevant standards of the World Health Organization and the State Food and Drug Administration.
Xu Nanping revealed that in the next step, he will continue to go all out to speed up the development of vaccines and never relax.
One is to accelerate the advancement of Phase III clinical trials and provide more vaccine products with different technical routes.
The second is to pay close attention to global virus mutations and related developments, and scientifically respond to ensure that the use of vaccines is not affected.
Third, continue to increase basic research on vaccines, build a national strategic scientific and technological force, and provide solid scientific and technological support for epidemic prevention and control.
National Health Commission:
The vaccination will be carried out in an orderly manner, and the eligible people will be
Zeng Yixin, deputy director of the National Health Commission, introduced at the press conference that we officially launched the vaccination of key populations in my country on December 15.
In the past two months, the cumulative vaccination of key populations across the country has exceeded 3 million doses.
In the inoculation work, we have established a series of systems such as complete rules for setting up vaccination sites, strict training of vaccination personnel, screening of recipients, monitoring of adverse reactions, emergency treatment and expert consultations for serious adverse reactions to ensure vaccination Work is safe and smooth.
The 3 million this time, plus the previous 1.5 million, fully prove that our vaccine is safe.
Zeng Yixin said that we will promote the vaccination of the elderly and high-risk groups with underlying diseases in an all-round and orderly manner, and follow-up vaccination for other general populations. At present, my country’s immunization planning expert advisory committee has formulated a unified vaccination plan. We will carry out vaccination in an orderly manner, so that all eligible people can achieve “sufficiency” and gradually build an immune barrier for the entire population to block The spread of the new crown virus has enabled the new crown pneumonia epidemic to be completely controlled.